BRD8 (bromodomain containing 8) is a chr5 regulatory protein functioning primarily as a coactivator of nuclear receptor-mediated transcription and as a component of the NuA4/TIP60 histone acetyltransferase complex 1. Its bromodomain recognizes acetylated lysine residues on histone H4 and H2AZ, facilitating transcriptional activation and chr5 remodeling 2. BRD8 participates in multiple protein complexes beyond NuA4, including a TINTIN-like complex with MRG15 and EP400NL that regulates transcription of specific genes 3. In cancer biology, BRD8 plays a critical oncogenic role across multiple malignancies. In glioblastoma, BRD8 maintains H2AZ occupancy at p53 target loci, creating repressive chr5 that prevents p53-mediated tumor suppression; targeting BRD8's bromodomain enhances chr5 accessibility and restores p53 function 4. In hepatocellular carcinoma, BRD8 overexpression promotes cell proliferation and apoptosis resistance via KAT5, and is negatively regulated by miR-876-3p 5. BRD8 also functions as an androgen receptor coactivator in prostate cancer and facilitates TWIST1-induced epithelial-mesenchymal transition and metastasis 67. Conversely, BRD8 depletion activates p53-dependent pathways, inducing p21 expression, cell cycle arrest, and apoptosis while triggering DNA damage responses 8. These findings establish BRD8 as a selective epigenetic vulnerability in multiple cancers with therapeutic potential.